IGF and myostatin pathways are respectively induced during the earlier and the later stages of skeletal muscle hypertrophy induced by clenbuterol, a β2-adrenergic agonist

Cell Biochemistry and Function

Volumn 30, Issue 8, 2012, Pages 671-676

  Abo, Tokuhisa ^a   Iida, Ryo Hei ^a   Kaneko, Syuhei ^a   Suga, Takeo ^a   Yamada, Hiroyuki ^a   Hamada, Yoshiki ^a   Yamane, Akira ^a  

^a TSURUMI UNIVERSITY   (Japan)

Author keywords

Clenbuterol; Hypertrophy; Masseter; Myostatin; Rat

Indexed keywords

CLENBUTEROL; MYOSTATIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; MASSETER MUSCLE; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ANIMALS; BLOTTING, WESTERN; CLENBUTEROL; HYPERTROPHY; MALE; MUSCLE, SKELETAL; MYOSTATIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SOMATOMEDINS; TIME FACTORS;

RATTUS;

EID: 84870708916     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2848     Document Type: Article

References (37)

1. 2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Reports 1984; 4: 83-91.
2. Benson DW, Foley-Nelson T, Chance WT, Zhang FS, James JH, Fischer JE. Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 1991; 50: 1-5.
3. Stevens L, Firinga C, Gohlsch B, Bastide B, Mounier Y, Pette D. Effects of unweighting and clenbuterol on myosin light and heavy chains in fast and slow muscles of rat. Am J Physiol Cell Physiol 2000; 279: C1558-C1563.
4. Oishi Y, Imoto K, Ogata T, Taniguchi K, Matsumoto H, Roy RR. Clenbuterol induces expression of multiple myosin heavy chain isoforms in rat soleus fibres. Acta Physiol Scand 2002; 176: 311-318.
5. Rajab P, Fox J, Riaz S, Tomlinson D, Ball D, Greenhaff PL. Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1076-R1081.
6. 2-adrenergic agonist, on the myofiber diameter, fiber type, and expressions of insulin-like growth factors in the adult mouse masseter muscle. Jpn J Oral Biol 2003; 45: 418-427.
7. Awede BL, Thissen JP, Lebacq J. Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am J Physiol Endocrinol Metab 2002; 282: E31-E37.
8. S6k in muscle showing clenbuterol-induced anabolism. Am J Physiol Endocrinol Metab 2001; 281: E676-E682.
9. Matsumoto T, Akutsu S, Wakana N, Morito M, Shimada A, Yamane A. The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat. Arch Oral Biol 2006; 51: 603-611. DOI:10.1016/j.archoralbio.2006.01.003.
10. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 1997; 387: 83-90.
11. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997; 94: 12457-12461.
12. Marchitelli C, Savarese MC, Crisa A, Nardone A, Marsan PA, Valentini A. Double muscling in Marchigiana beef breed is caused by a stop codon in the third exon of myostatin gene. Mamm Genome 2003; 14: 392-395. DOI:10.1007/s00335-002-2176-5.
13. Kambadur R, Sharma M, Smith TP, Bass JJ. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997; 7: 910-916. DOI:10.1101/gr.7.9.910.
14. Grobet L, Martin LJ, Poncelet D, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997; 17: 71-74.
15. 2 adrenergic agonist. Br J Pharmacol 2006; 147: 412-421. DOI:10.1038/sj.bjp.0706625.
16. Yamane A. Embryonic and postnatal development of masticatory and tongue muscles. Cell Tissue Res 2005; 322: 183-189. DOI:10.1007/s00441-005-0019-x.
17. Yamane A, Fukui T. Characteristics of masticatory and tongue muscle. J Oral Biosci 2007; 49: 206-210.
18. 2-Adrenergic Agonist, on Sizes of Masseter, Temporalis, Digastric, and Tongue muscles. Open Dent J 2009; 3: 191-196.
19. Adams GR, Cheng DC, Haddad F, Baldwin KM. Skeletal muscle hypertrophy in response to isometric, lengthening, and shortening training bouts of equivalent duration. J Appl Physiol 2004; 96: 1613-1618. DOI:10.1152/japplphysiol.01162.2003.
20. Adams GR. Role of insulin-like growth factor-I in the regulation of skeletal muscle adaptation to increased loading. Exerc Sport Sci Rev 1998; 26: 31-60.
21. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995; 16: 3-34.
22. Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996; 17: 481-517.
23. Yamane A, Mayo ML, Shuler C. The expression of insulin-like growth factor-I, II and their cognate receptor 1 and 2 during mouse tongue embryonic and neonatal development. Zool Sci 2000; 17: 935-945. DOI:10.2108/zsj.17.935.
24. Yamane A, Urushiyama T, Diekwisch TGH. Roles of insulin-like growth factors and their binding proteins in the differentiation of mouse tongue myoblasts. Int J Dev Biol 2002; 46: 807-816.
25. Urushiyama T, Akutsu S, Miyazaki J, Fukui T, Diekwisch TG, Yamane A. Change from a hard to soft diet alters the expression of insulin-like growth factors, their receptors, and binding proteins in association with atrophy in adult mouse masseter muscle. Cell Tissue Res 2004; 315: 97-105. DOI:10.1007/s00441-003-0787-0.
26. Yamane A, Amano O, Slavkin HC. Insulin-like growth factors, hepatocyte growth factor and transforming growth factor-α in mouse tongue myogenesis. Dev Growth Differ 2003; 45: 1-6.
27. Musaro A, McCullagh KJA, Naya FJ, Olson EN, Rosenthal N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 1999; 400: 581-585.
28. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biol 2001; 3: 1009-1013.
29. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000; 278: E967-E976.
30. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002; 175: 19-31.
31. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor β -like signaling pathway to block adipogenesis. Mol Cell Biol 2003; 23: 7230-7242. DOI:10.1128/MCB.23.20.7230-7242.2003.
32. Joulia-Ekaza D, Cabello G. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 2006; 312: 2401-2414. DOI:10.1016/j.yexcr.2006.04.012.
33. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF- β superfamily signalling. Genes Cells 2002; 7: 1191-1204.
34. Attisano L, Tuen Lee-Hoeflich S. The Smads. Genome Biol 2001; 2: REVIEWS3010.
35. Reisz-Porszasz S, Bhasin S, Artaza JN, et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 2003; 285: E876-E888. DOI:10.1152-ajpendo.00107.2003.
36. Durieux AC, Amirouche A, Banzet S, et al. Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology 2007; 148: 3140-3147. DOI:10.1210/en.2006-1500.
37. Ishii DN. Relationship of insulin-like growth factor II gene expression in muscle to synaptogenesis. Proc Natl Acad Sci USA 1989; 86: 2898-2902.